About Us:
Foundation News
About Us: Foundation News
The Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics have entered a new collaboration focused on regenerative medicine to further advance scientific research in SMA and other neuromuscular disorders. Recent FDA approvals of several disease modifying therapies for SMA has made regenerative medicine approaches the next frontier in drug discovery and development. The SMA Foundation-PTC…
The Spinal Muscular Atrophy (SMA) Foundation, a non-profit, organization whose mission is to accelerate the development of treatments for SMA, the leading cause of genetic death in young children, visited the Nasdaq MarketSite in Times Square on August 17, 2018. In honor of the occasion, Dinakar Singh, Co-Founder and Chairman of the Board of Directors,…
February 24, 2006 – PsychoGenics Inc. Tarrytown, New York and the Spinal Muscular Atrophy (SMA) Foundation New York, NY – have extended their research agreement to establish and behaviorally phenotype transgenic in vivo models of SMA and test potential therapeutics using these models. As part of this collaborative agreement PsychoGenics has established self-sustaining transgenic SMA colonies…
New York, NY — January 31, 2006 – The Spinal Muscular Atrophy Foundation announced the completion of a new licensing agreement that will facilitate access to intellectual property fundamental to drug discovery efforts for the disease. Spinal muscular atrophy (SMA) is the leading genetic killer of infants and toddlers; there is no known treatment or cure.…
New York, NY – October 4, 2005 – The Spinal Muscular Atrophy Foundation announced an agreement today with Regeneron Pharmaceuticals, Inc. to develop new animal models of spinal muscular atrophy (SMA), the leading genetic cause of mortality in infants and toddlers.. The collaboration will exploit Regeneron’s proprietary VelocigeneTM technology to rapidly generate and test new…
New York, NY – May 17, 2005 – The Spinal Muscular Atrophy Foundation today announced the addition of six members to its Scientific Advisory Board. The new advisors, some of the most wellrespected individuals in their fields, were specifically sought for the wealth of experience they bring to bear on Foundation efforts to advance drug…
New York, NY – March 03, 2005 – Researchers at Columbia University have received more than $3 million in funding from the Spinal Muscular Atrophy Foundation to conduct research on spinal muscular atrophy (SMA), a neuromuscular disease that is the leading genetic killer of infants and toddlers. The funding will enable the institution to significantly expand…
by Paroma Basu Scientists grow critical nerve cells MADISON, WI — January 31, 2005 – After years of trial and error, scientists have coaxed human embryonic stem cells to become spinal motor neurons, critical nervous system pathways that relay messages from the brain to the rest of the body. The new findings, reported online Jan. 30 in…
New York, NY – November 29, 2004 – Using a newly developed technology, a team of Columbia University researchers has uncovered that indoprofen, a nonsteroidal anti-inflammatory drug, may increase the production of a protein lacking in patients with spinal muscular atrophy (SMA), a fatal pediatric genetic disease. It is the scientists’ hope that the discovery will…
New York, NY – November 29, 2004 – The Spinal Muscular Atrophy Foundation, a nonprofit organization dedicated to finding a treatment or cure for spinal muscular atrophy (SMA) – the leading genetic killer of infants and toddlers – announced that is has funded more than $15 million in research in the last 18 months. Projects were…
Bar Harbor, Maine – October 21, 2004 – The Jackson Laboratory is pleased to announce that it has received support from the Spinal Muscular Atrophy Foundation to make available the first group of mouse models for spinal muscular atrophy (SMA), a neuromuscular disease and the leading genetic cause of death among infants and toddlers. The…
New York, NY – September 24, 2004 – Researchers at Columbia University, Children’s Hospital Boston and The Children’s Hospital of Philadelphia have established a clinical research network to study spinal muscular atrophy (SMA), the leading genetic killer of infants and toddlers. The Pediatric Neuromuscular Clinical Research Network will address the vital need in SMA research to…